Imatinib treatment of chronic myeloid leukemia cell lines: KU-812, KCL-22 and JURL-MK1
Summary:
Analysis of CML cell lines (KU-812, KCL-22, and JURL-MK1) treated with tyrosine kinase inhibitor imatinib. Imatinib inhibits oncogenic BCR-ABL1, a tyrosine kinase present in most CML patients. Results provide insight into molecular mechanisms underlying imatinib inhibition of CML.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citations:
Duy C, Hurtz C, Shojaee S, Cerchietti L et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011 May 19;473(7347):384-8. PMID: 21593872
Hurtz C, Hatzi K, Cerchietti L, Braig M et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 2011 Oct 24;208(11):2163-74. PMID: 21911423
